Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

India’s Ipca acquires U.S. drug contractor

by Rick Mullin
January 29, 2018 | A version of this story appeared in Volume 96, Issue 5

The Indian drug services firm Ipca Laboratories has purchased Pisgah Labs, a contract manufacturer of active pharmaceutical ingredients (APIs) in Pisgah Forest, N.C., for $9.7 million. The deal follows Ipca’s 2015 acquisition of Onyx Scientific, a U.K.-based specialist in custom synthesis, solid-state chemistry, and small-scale drug chemical production. Ipca says Pisgah will allow it to manufacture small-volume APIs in the U.S. as well.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.